The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis

//The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis

The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis

Omakase Consulting continues its focus and work on contributing to the generation of evidence and advancing on the application of tools to informed decision making in healthcare and in particular in the rare diseases space. Proud to have had the opportunity to co-author a study to determine the relative value contribution of fenfluramine for the treatment of Dravet syndrome in Spain through MCDA methodology.
Dravet syndrome (DS) is considered a severe, rare disease with significant unmet needs and affecting patients from very early age. The study focuses on the determination of the relative value contribution of a new treatment for DS, Fintepla® (fenfluramine) compared to available alternatives by a multistakeholder panel of clinicians, patient representatives, hospital pharmacists and regional decision makers in Spain. It does highlight the critical unmet needs associated with a disease associated with important clinical comorbidities (including increased death risk), high impact on the healthcare system and that severely affects patients and their relatives in many aspects, including economic and quality of life.
The study has been published in Epilepsy & Behavior and can be download here: https://www.sciencedirect.com/science/article/pii/S1525505022001603

2022-06-22T15:53:01+00:00June 22nd, 2022|Articles|